Showing 951-960 of 3390 results for "".
Antibiotics and the Mutant Selection Window
https://practicaldermatology.com/topics/atopic-dermatitis/antibiotics-and-the-mutant-protection-window/19537/When considering antibiotics for treating acne, Hilary Baldwin, MD says there's a new concept dermatologists should consider in preventing antibiotic resistance. She describes the mutant selection window and why a higher dose antibiotic may actually be safer and more effective.The State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.The Importance of Skincare
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-importance-of-skincare/19035/Whether patients want lasers, injectables, Botox, or cosmeceuticals, they need guidance on proper skincare to prevent wrinkles and skin cancer, says Dina Anderson, MD, FAAD. Patients need to learn about antioxidants, free radicals, and the effects of smoking.Heliocare in Practice
https://practicaldermatology.com/topics/practice-management/heliocare-in-practice/19220/Polypodium leucotomos extract, which is derived from a tropical fern, offers benefits to users by minimizing some of the damage to the skin caused by exposure to visible light—UVA and UVB radiation—as well as invisible infrared light. Vivian Bucay, MD, discusses its activity and its role as a dispenASDS Survey: 8 Million Procedures in 2012
https://practicaldermatology.com/topics/practice-management/asds-survey-8-million-procedures-in-2012/19259/"More and more people are seeking care from dermatologic surgeons." ASDS President Timothy Flynn, MD addresses new findings about the public's dependence on dermatologic surgeons. Derm surgeons' expertise and training in cosmetic and medical care are discussed.ILDS Joins the Lancet Commission on Skin Health
https://practicaldermatology.com/series/skin-minute/ilds-joins-the-lancet-commission-on-skin-health/57085/Esther Freeman, MD, talks about the International League of Dermatologic Society (ILDS) and its new contributions to The Lancet’s new Commission focusing exclusively on skin health. It’s the first time the publication has devoted one of its highly regarded Commissions on skin health.DermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis Bioteherapu